Octreotide scanning for carcinoid tumours.
The somatostatin analogue octreotide may be used in the diagnosis of carcinoid and other neuroendocrine tumours. Radionuclide scanning following intravenous injection of 111Indium-labelled octreotide (111In-DTPA-pentetreotide) provides a sensitive, non-invasive method of localising somatostatin-positive tumours. The technique may also be used to identify patients who may respond to 'cold' octreotide therapy and to monitor therapeutic efficacy.
Critchley
M
M
Department of Nuclear Medicine, Royal Liverpool University Hospital, UK.
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002276:Carcinoid Tumor / Q000000981:diagnostic imaging* / Q000188:drug therapy; D006801:Humans; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging / Q000188:drug therapy; D015282:Octreotide / Q000627:therapeutic use; D015899:Tomography, Emission-Computed, Single-Photon
D018931:Antineoplastic Agents, Hormonal; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D019797:3-Iodobenzylguanidine; D015282:Octreotide